In this issue of Blood, Zambetti et al validate that palmitoylation of mutant NRAS is essential for its oncogenic function by using a genetic mouse model. Their study highlights that the palmitoylation/depalmitoylation cycle is an attractive candidate for therapeutic intervention in hematologic malignancies with NRAS mutations.(1)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
